Imatinib Eg (Imatinib)

Imatinib Eg targets specific tyrosine‑kinase driven malignancies and is employed in the following indications:

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by inhibiting the BCR‑ABL fusion protein.
• Gastrointestinal stromal tumor (GIST): blocks KIT‑driven tumor growth, leading to disease control.

• Imatinib binds competitively to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition halts signal transduction pathways that drive cell proliferation and survival, resulting in apoptosis of malignant cells that depend on these kinases.

Adverse reactions may occur with Imatinib therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent, usually self‑limiting.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, may be watery.
• Rash: maculopapular skin eruption.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiac failure: signs of reduced cardiac output.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: increased pressure in lung arteries.
• Tumor lysis syndrome: metabolic disturbances from rapid tumor breakdown.

Before initiating Imatinib, clinicians should consider several safety measures.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess liver function: check transaminases and bilirubin periodically.
• Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac risk.
• Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs.
• Use caution in pregnancy: benefits must outweigh potential fetal risk.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct light.

Imatinib may interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib exposure.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic levels.
• Concomitant use with QT‑prolonging agents (e.g., sotalol): heightened risk of arrhythmia.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates with narrow therapeutic index (e.g., midazolam, cyclosporine): adjust dose as needed.
• Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.
• Vaccines (live attenuated): monitor immune response, consider timing of administration.